Department of Vascular Surgery, Shandong Provincial Hospital, Shandong University, Jinan, People's Republic of China.
Mol Biol Rep. 2010 Mar;37(3):1467-75. doi: 10.1007/s11033-009-9541-3. Epub 2009 May 12.
Transplantation of adult marrow stromal cells (MSCs) has been developed as a new method of treating severe ischemia diseases by therapeutic angiogenesis. Erythropoietin (EPO) is capable of inducing angiogenesis and inhibiting MSCs apoptosis. The effect of EPO on the therapeutic potency of MSCs transplantation in a rat model of limb ischemia was investigated in the current study. The results indicate that the combined treatment with MSC transplantation and EPO infusion is superior to MSC transplantation alone in the treatment of limb ischemia. MSCs transplantation and EPO infusion could enhance the angiogenic effect of each other to achieve a better therapeutic effect. This combination therapy may become a more effective approach for ischemia diseases of the limbs.
成体骨髓基质细胞(MSCs)的移植已被开发为一种通过治疗性血管生成来治疗严重缺血性疾病的新方法。促红细胞生成素(EPO)能够诱导血管生成和抑制 MSCs 凋亡。本研究旨在探讨 EPO 对大鼠肢体缺血模型中 MSCs 移植治疗效果的影响。结果表明,与单独 MSC 移植相比,MSC 移植联合 EPO 输注治疗肢体缺血的效果更佳。MSC 移植和 EPO 输注可以增强彼此的促血管生成作用,从而达到更好的治疗效果。这种联合治疗可能成为治疗肢体缺血性疾病的更有效方法。